Blog

Ashish Manne: The Potential of Cell-Free DNA Methylation Sequencing in Pancreatic Ductal Adenocarcinoma

Ashish Manne/X

May 28, 2025, 10:09

Ashish Manne: The Potential of Cell-Free DNA Methylation Sequencing in Pancreatic Ductal Adenocarcinoma

Ashish Manne, GI Medical Oncologist and Associate Professor at Ohio State University Comprehensive Cancer Center, shared a post on LinkedIn:

“Excited to share that we’ll be presenting our latest work at ASCO25!

Our poster highlights the potential of cell-free DNA methylation sequencing to better understand and predict treatment response in pancreatic ductal adenocarcinoma (PDA).

This work reflects our continued focus on decoding the biology of PDA — because in this disease, Biology Is King.

Looking forward to connecting with colleagues and collaborators in Chicago!”

Ashish Manne announced his team’s upcoming presentation at ASCO 2025, focusing on the use of cfDNA methylation sequencing to improve treatment response prediction in pancreatic ductal adenocarcinoma.

More posts on Adenocarcinoma on OncoDaily.

Adenocarcinoma ASCO25 Ashish Manne cancer Cell-Free DNA Methylation Sequencing Chicago fight against cancer Global fight against cancer James Cancer Hospital Ohio State University Comprehensive Cancer Center OncoDaily Oncology pancreatic ductal adenocarcinoma

USA vs Europe: Who Does Cancer Screening Better?

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action